News

KeViRx, Inc selected as part of BLUE KNIGHT™ collaboration for global health preparedness

Charlottesville, Virginia – KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services. 

Blue Knight is a collaborative program designed to anticipate and respond to global health security threats. Blue Knight provides a scientific and technological ecosystem for innovative, early stage startup companies to develop technologies that are strategically aligned with global health interests. KeViRx was selected for this program based on its platform small molecule technology, KVX-053, which displays efficacy in preclinical models of ovarian cancer, acute myeloid leukemia and acute lung injury.  As a Blue Knight company with a footprint at JLABS @ Washington, DC, KeViRx will benefit from dedicated mentorship and unique benefits from BARDA, in addition to access to the Johnson & Johnson Innovation extensive global network of innovators for critical insights centering on KVX-053 development.

“KeViRx is honored to be selected to be a Blue Knight company and we are excited to be working with the Blue Knight program. We are optimistic that the program will help advance our KVX-053 platform for global health applications in the present and the future,” said Dr. John S. Lazo, who serves as KeViRx’s Chief Scientific Officer.

Read more here.

Recent News

08/26/2025

Activation Capital Names Michael Steele as President and CEO

The Virginia Biotechnology Research Partnership Authority (doing business as Activation Capital) announced today that it has appointed Michael Steele as president and chief executive officer. Steele succeeds Robert Ward, who has served as interim CEO since July 2024 during a period of rapid growth for the life sciences ecosystem development organization. Steele comes to Activation

08/25/2025

Danforth Advisors Acquires PharmaDirections

Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization. Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and

08/22/2025

ivWatch Technology Linked to Major Reduction in Severe IV Injuries in Newborns Over Four-Year Study

A study published this month in The BMJ (British Medical Journal) analyzed the use of optical sensor technology from ivWatch, the U.S.-based IV safety company, in the early detection of peripheral intravenous infiltration or extravasation (PIVIE) events in neonates. Presenting a comparative evaluation between conventional observational methods and continuous sensor-based monitoring, the study offers insights